Cover photo
Teva Pharmaceutical Industries Ltd.


“Japan is one of the fastest growing generics markets in the world, and we expect its high growth to continue driven by social requirements such as increased patients' needs for a stable supply of affordable high quality medicines and reduction of healthcare expenditures. We believe that we can contribute to the healthcare industry, medical professionals and most important, patients in Japan,” said Siggi Olafsson, President and CEO of Teva Global Generic Medicines.
Read the full  press release: 
JERUSALEM & OSAKA, Japan--(BUSINESS WIRE)--Mar. 31, 2016-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) and Takeda Pharmaceutical Comp, Takeda and Teva Establish “Teva Takeda Yakuhin Ltd.” in Japan
Add a comment...
There have been reports about a recruiting scam targeting our company, involving “online interviews” for open and virtual positions at Teva.  Please be aware that Teva Pharmaceuticals in no way endorsed or initiated these fraudulent communications, and you should always verify that the contact and source are legitimate before providing any personal and/or monetary details. This scam directs potential job applicants to an online chat-room interview and often includes immediate job offers.  Please feel free to contact us by direct message if you believe you have been approached by a potentially fraudulent interviewer.
You can always find official company information at as well as job postings on Linkedin
Add a comment...
As the industry’s leading global supplier of APIs (active pharmaceutical ingredients), TAPI (Teva API) is committed to providing the best online customer experience possible. Check out the new TAPI website, with user-friendly tools and new features!
This is how we plan to change the game - from service to experience Read More. TopLeftText. Product Catalog 14/03/2016. Looking for APIs? Explore our new Product Catalog Read More. TopLeftText. News - file updates 14/03/2016. View information about recent DMF and CEP files Read More. TopLeftText ...
Add a comment...
Today we recognize the women of Teva, who are leaders, mentors, contributors, innovators and more. We are excited and proud to be part of an organization which empowers and engages the many diverse and talented people in Teva, of all genders and backgrounds. Share the inspiration!
Add a comment...
Teva Completes Acquisition of Rimsa
“Building on Rimsa’s strong brand reputation and well-established commercial footprint, together, we will now be able provide a world-class offering of specialty and generic Teva medicines to patients in Mexico and across the region," said Siggi Olafsson, President and CEO of Teva Global Generic Medicines. 
Read the full press release:
Add a comment...
Have them in circles
881 people
raman thakur's profile photo
Tomas Petrla's profile photo
Ektha Rathod's profile photo
Luca Zuffi's profile photo
Artemio Gálvez Azañero's profile photo
My Asia's profile photo
Hitesh Parmar's profile photo
Tom Brooks's profile photo
abbas shah's profile photo
Partnering for Success in an Ever-Shifting World:  
Teva’s Siggi Olafsson and P&G’s Tom Finn gave a fascinating interactive talk at the Skolkovo Moscow School of Management in Russia, highlighting our pioneering joint venture, PGT Healthcare. It gave us an opportunity to share our experience with the business community through open dialogue, and our aspiration to meet patient needs all over the world.
The discussion explored the latest business models, innovative solutions, cutting-edge technologies and most effective systems for managing business processes in an environment of constant change, as well as plans and prospects for the future.  Not only did we impart the latest news and insights, but also evoked a warm response and very positive feedback from our Russian team and all participants.
Add a comment...
Teva expands its asthma portfolio, broadening the range of medicines available to control and prevent of asthma symptoms in children ages 12 months to 8 years. 
Add a comment...
When hundreds of Teva ratiopharm sales reps in Germany come together to celebrate excellence, we get a view from the top!  
This year’s annual meeting recognized Teva Germany’s leadership in continuing to make quality healthcare accessible, and had employees literally ‘kicking off’ (footballs and) plans for the upcoming year in a sports-themed event with friendly competition among colleagues. 
The sales teams also had the opportunity to visit and learn about Teva’s German headquarters in Ulm, including a stop at the Ulm Minster where this photo was taken. 
(Photo credit:
Add a comment...
Teva Respiratory is scheduled to present new #asthma data at the 2016 American Academy of Allergy, Asthma and Immunology Annual Meeting from March 4-7 in Los Angeles, CA. If you are attending the meeting, be sure to check out our press release for specific dates/times of poster and oral presentations.  A big congrats to all of those involved in the research! #AAAAI16
Add a comment...
Proper disposal of unused, unwanted, or expired medicines is an important—and simple—way to keep you, your family, and your community safe.
Add a comment...
Personalized Medicine is increasingly being used to tailor medical treatment to the individual characteristics of each patient: The right treatment, at the right dose, for the right person.
Personalized Medicine is increasingly being used to tailor medical treatment to the individual characteristics of each patient: The right treatment, at the right dose, for the right person
Add a comment...
Improving health, and making millions of people around the world feel better.

This is the official Google+ page for Teva Pharmaceutical Industries Ltd. 

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by millions of patients every day. 

Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,000 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. 

Teva's net revenues in 2015 amounted to $19.7 billion. For more information, visit

Note to Users: This page is intended to provide news and updates about our company, and Teva reserves the right to delete any comments that it considers to be inappropriate, abusive or spam. 

Adverse events for any of our products should be reported to: 

Product-specific questions should be directed to Teva or Teva Group subsidiaries in your country. Contact details may be found here: